Ipamorelin
Ipamorelin, also called NNC 26-0161, is a lab-made peptide that prompts the pituitary gland to release a short pulse of the body's own growth hormone. It has been tested in healthy volunteers and in a trial of slow gut recovery after bowel surgery, where it did not show benefit.
At a glance
- Hormone-related
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- 200 mcg per Peptide Dosing Protocols. All 3 sources
- 10 mg in 3 mL
How much to draw
Full calculator →Opened on 200 mcg, the figure Peptide Dosing Protocols reports for Ipamorelin, and a 10 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Ipamorelin or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 200-300 mcg per injection | not stated8-12 weeks, then 2-4 weeks off · Repeatable | subcutaneous | Peptide Protocol Wiki |
| Standard: 200-300 mcg/day · Low: 100 mcg/day · High: 300 mcg | 1-3 times per day8-12 weeks on, then 4 weeks off · 8-12 weeks | subcutaneous | Peptide Dosing ProtocolsWhat it saysHideHalf-life: about two hours. Most research protocols use 100 to 300 mcg per shot, one to three times per day. |
| Referenced at 100-300 mcg (0.1-0.3 mg) per dose. Commonly paired with CJC-1295 for synergistic GH release with minimal cortisol or prolactin elevation. Sample stacks cite 100 mcg each, fasted morning and before bed. | 2-3x daily (vitality contexts cite once daily) · Morning fasted, pre-workout, or before bedOn-cycle 8-12 weeks, off-cycle 4 weeks | subcutaneous | Peptide Therapy Reference TextWhat it saysHideAug 2026), secondary reference; provider confirmation required. |
- not stated8-12 weeks, then 2-4 weeks off · Repeatable
- subcutaneous
- Peptide Protocol Wiki
- 1-3 times per day8-12 weeks on, then 4 weeks off · 8-12 weeks
- subcutaneous
- Peptide Dosing Protocols
What it saysHide
Half-life: about two hours. Most research protocols use 100 to 300 mcg per shot, one to three times per day.
- 2-3x daily (vitality contexts cite once daily) · Morning fasted, pre-workout, or before bedOn-cycle 8-12 weeks, off-cycle 4 weeks
- subcutaneous
- Peptide Therapy Reference Text
What it saysHide
Aug 2026), secondary reference; provider confirmation required.
- Bacteriostatic water
- 3.0 mL BAC water for 10 mg vial
You will almost never hear ipamorelin mentioned without CJC-1295, and there is a real reason researchers pair them.
We have not published an audit on Ipamorelin. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
It presses a release button on the pituitary gland, and the gland puts out a short pulse of growth hormone that resembles the body's own pattern rather than a constant supply. Researchers link this to the GHS-R1a receptor, the same one the hunger hormone ghrelin uses, to a brief easing of the somatostatin brake on growth hormone release, and to IGF-1, which the liver makes from growth hormone and which drives most of the downstream effects. In lab studies it did not raise cortisol, ACTH or prolactin even well above the doses needed to release growth hormone, unlike GHRP-2 and GHRP-6. No clinical trial has tested it for the body-composition or anti-aging uses people discuss today, so the dose ranges and schedules in circulation come from community protocols rather than validated evidence.
Ghrelin-receptor agonist; GH release signaling.
Reported side effects
Seen in studies: in a Phase II trial of 117 bowel surgery patients, ipamorelin given by vein twice daily for up to 7 days produced treatment-related adverse event rates similar to placebo. The trial missed its efficacy endpoint, but tolerability was not why the programme stopped. Lab testing found no rise in cortisol, ACTH or prolactin at standard growth-hormone-releasing doses.
Reported by users: mild short-lived headache, light water retention or bloating, a mild increase in appetite, and tingling in the hands or feet, mostly early in a cycle. At higher doses or with longer use, reports add mild joint stiffness, temporary fatigue and carpal tunnel-style symptoms linked to fluid retention. Some report mild redness, stinging or a small bump at the injection site.
Not ruled out: most ipamorelin sold comes from research-use suppliers rather than pharmacies, so quality varies and content is not guaranteed.
Who should avoid it
People with active or recent cancer: growth hormone and IGF-1 can support cell growth.
People with uncontrolled type 1 or type 2 diabetes: growth hormone affects insulin sensitivity, so glucose control can shift.
People with severe heart disease: growth hormone can cause fluid retention, which can strain an already weak heart.
People who are pregnant or breastfeeding: there is no safety data for either group.
Children and teenagers: growth hormone and IGF-1 act directly on growth plates, so it is not for anyone still growing.
Competitive athletes: ipamorelin and all ghrelin mimetics are banned under WADA rules.
People with a strong family history of cancer, pre-diabetes or high-normal fasting glucose, medications that affect blood sugar, sleep apnea, or carpal tunnel symptoms: these are listed as extra-caution groups, since growth hormone can worsen sleep apnea and the related fluid retention can flare carpal tunnel symptoms.
What gets monitored
Fasting glucose and HbA1c before and during extended ipamorelin protocols. (reported by Peptide Dosing Protocols)
Common questions
What is ipamorelin?
It is a research peptide that signals the pituitary gland to release the body's own growth hormone in short, natural pulses. It does this through the GHS-R1a receptor, the same receptor the hunger hormone ghrelin uses.
What dose of ipamorelin do research protocols describe?
Reported amounts and schedules for Ipamorelin differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What does the ipamorelin dosage chart by vial size show?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
How is ipamorelin reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
What is ipamorelin's half-life?
About 2 hours. A Phase I study in 40 healthy male volunteers found dose-proportional pharmacokinetics, that terminal half-life, and peak growth hormone around 40 minutes after the shot. The short half-life is why each shot makes one pulse and then fades.
Is ipamorelin FDA-approved?
No, it is not approved for any human use. Its clinical programme was tested for slow gut recovery after bowel surgery and was discontinued after it failed to show benefit for that endpoint.
What ipamorelin dosage do protocols describe for women?
Reported amounts and schedules for Ipamorelin differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What ipamorelin dosing schedule do beginner protocols describe?
Reported amounts and schedules for Ipamorelin differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.
MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.
This is a combination of two growth hormone compounds sold in a single vial: tesamorelin, a synthetic copy of growth hormone-releasing hormone, and ipamorelin, a ghrelin mimic that acts as a growth hormone secretagogue. It is sold for research use and is studied in the context of the growth hormone system, visceral fat and recovery.
Epitalon, also spelled epithalon, is a lab-made peptide of four amino acids (Ala-Glu-Asp-Gly), also called AEDG. It is studied mainly for aging, in cells, in animals and in older non-blinded human work on the related pineal extract.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.